---
title: "Pulse Biosciences, Inc. (PLSE.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PLSE.US/overview.md"
symbol: "PLSE.US"
name: "Pulse Biosciences, Inc."
parent: "https://longbridge.com/en/quote/PLSE.US.md"
datetime: "2026-04-15T23:13:35.101Z"
locales:
  - [en](https://longbridge.com/en/quote/PLSE.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PLSE.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PLSE.US/overview.md)
---

# Pulse Biosciences, Inc. (PLSE.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Address | 601 Brickell Key Drive, Suite 1080, Miami, Florida, United States |
| Website | [www.pulsebiosciences.com](https://www.pulsebiosciences.com) |

## Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc.

## Key Executives

| Name | Title |
|------|-------|
| Paul Arthur LaViolette | President, CEO & Co-Chairman of the Board |
| Robert W. Duggan | Independent Co-Chairman |
| Darrin R. Uecker | CTO & Director |
| Jon Skinner | Chief Financial Officer |
| Liane Teplitsky | Chief Operating Officer |
| Steven T. Weber | VP of Accounting, Principal Accounting Officer & Global Corporate Controller |
| Manmeet Singh Soni | Lead Independent Director |
| Mahkam Zanganeh | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Robert W. Duggan | 70.83% | 2025-10-22 |
| BlackRock, Inc. | 2.00% | 2025-12-31 |
| The Vanguard Group, Inc. | 1.65% | 2025-12-31 |
| Mahkam Zanganeh | 1.28% | 2025-10-22 |
| Bank of America Corporation | 1.18% | 2025-12-31 |
| Genius Inc. | 0.93% | 2025-10-22 |
| Geode Capital Management, LLC | 0.68% | 2025-12-31 |
| State Street Global Advisors, Inc. | 0.66% | 2025-12-31 |
| Portolan Capital Management, LLC | 0.58% | 2025-12-31 |
| Darrin R. Uecker | 0.42% | 2025-10-22 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Surgical & Medical Equipment | 350000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Pulse Biosciences, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Surgical & Medical Equipment",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**